Pfizer touts strength of RSV vaccine in subgroup of younger immunocompromised patients
A few months after touting its RSV vaccine’s effects on younger adults, Pfizer said a sub-study focusing on immunocompromised adults is also positive. The data …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
